- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01863901
Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device
A Prospective, Non-Randomized, Unblinded Study Evaluating the Treatment With the Cryo-Touch III Device for Upper Limb Spasticity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Spasticity, common in neurological disorders, is part of the upper motor neuron syndrome displaying increased tone, clonus, spasms, spastic dystonia and co- contractions. The impact of spasticity on the patient varies from a subtle neurological sign to severe spasticity causing pain and contractures. Upper limb spasticity (ULS) is the rapid contraction or shortening of the muscles in the arm causing abnormal muscle movements in the elbow, wrist and fingers. It has been reported that over 1 million Americans with traumatic injury to the brain or spinal cord, stroke, multiple sclerosis and cerebral palsy experience ULS. Tightly clenched fists, twisted wrist and elbow joints, and fixed arms in flexed positions result in extreme discomfort, pain and spasm. A nonsurgical, minimally invasive, effective approach to pain associated with ULS is desirable.
Myoscience, Inc. (Redwood City, CA) has developed a pain management device - the Cryo-Touch III - for a novel, minimally invasive procedure using focused cold therapy to target sensory nerve tissue and offer long-lasting pain relief through cryoanalgesia. The device operates on the well-established cryobiology principle that localized exposure to controlled, moderately low temperature conditions can alter tissue function. The therapy treats nerves via a probe in the form of an assembly of small diameter needles, creating a highly localized, low temperature treatment zone around the probe. This focused cold therapy creates a conduction block that prevents nerve signaling. Prior studies of the Cryo-Touch, Cryo-Touch II, Cryo-Touch III (a.k.a. PCP 1.0) devices have provided preliminary evidence of effectiveness on motor nerves and have been shown to be safe with no serious device-related adverse events.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kansas
-
Overland Park, Kansas, United States, 66211
- Kansas City Bone and Joint Clinic
-
-
Pennsylvania
-
Paoli, Pennsylvania, United States, 19301
- Dr. Mitchell Paulin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, 18 years of age and older.
- Trial participants must have a confirmed diagnosis that results in spasticity involving muscle innervated by the musculocutaneous nerve (MCN).
- Any medications must be maintained on a stable schedule for at least two weeks prior to treatment. No washout period is allowed.
- Must have an average score on the Modified Ashworth Scale for Spasticity of ≥ 2 over the last 30 days in the elbow.
- Subject, in the Investigator's opinion, will not be exposed to unacceptable risk by participation.
Exclusion Criteria:
- Previous surgical intervention that altered the target neural anatomy of the upper limb.
- Any injection (neurolytic, sclerosing, anesthetic, etc.) to the upper limb within the last 4 months.
- Current enrollment in an investigational drug or device study that specifically targets spasticity management.
- Allergy or intolerance to local anesthesia.
- Any local skin condition at the treatment site that in the investigator's opinion would adversely affect treatment or outcomes.
- Any chronic medication use (prescription, over-the-counter, etc.) that in the investigator's opinion would affect study participation or subject safety.
- Diagnosis of cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, open and/or infected wounds.
- Diagnosis of progressive neurologic diseases such as ALS.
- For any reason, in the opinion of the investigator, the subject may not be a suitable candidate for study participation (i.e., history of noncompliance, drug dependency, any related upper limb injury, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with the Cryo-Touch III Device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in Pain and Symptoms Caused by Hypertonia in the Upper Arm as Measured by an Improvement of 1 Point or Greater on the Modified Ashworth Scale (MAS) at Day 7
Time Frame: Baseline to: post-treatment (Day 0), Day 7, Day 30
|
The Modified Ashworth Scale (MAS) is 6-point scale designed to assess muscle tone and spasticity through the flexion or extension of a joint.
Muscle response is graded on a scale from 0 (no increase in muscle tone) to 4 (affected parts rigid in flexion or extension).
This includes a 1+ rating, which further distinguishes the types of increase in muscle tone from those described by a 1 or 2 rating.
|
Baseline to: post-treatment (Day 0), Day 7, Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in Spasticity as Measured by the Tardieu Scale
Time Frame: Baseline to: post-treatment (Day 0), Day 7, Day 30
|
The Tardieu Scale uses the application of stretch at several velocities to quantify muscle response and assess muscle spasticity.
Two specified velocities were assessed (V1 and V2).
For each stretch, quality of muscle reaction (X) is recorded on a 6-point scale from 0 (no resistance throughout passive movement) to 5 (immovable joint).
|
Baseline to: post-treatment (Day 0), Day 7, Day 30
|
Improvement in Spasm Frequency and Severity as Measured by the Penn Spasm Score
Time Frame: Baseline to: post-treatment (Day 0), Day 7, Day 30
|
The Penn Spasm Score, which is a patient reported score, consists of two sub-scales: the spasm frequency score and the spasm severity scale3.
The Penn spasm frequency is assessed on a 5-point scale from 0 (no spasms) to 4 (spasms occurring more than ten times per hour).
The spasm severity scale consists of three ratings, which are 1 (mild), 2 (moderate) and 3 (severe).
|
Baseline to: post-treatment (Day 0), Day 7, Day 30
|
Improvement in Upper Extremity Motor Recovery as Measured by the Fugl-Meyer Scale (Post Stroke Subjects Only)
Time Frame: Baseline to: post-treatment (Day 0), Day 7, Day 30
|
The Fugl-Meyer Scale is an assessment consisting of 33 movements, each rated as "0" (cannot perform), "1" (can partially perform) or "2" (can perform fully).
A Subject's score is the sum of their ratings on each of these items, where the maximum (best) score is a 66.
|
Baseline to: post-treatment (Day 0), Day 7, Day 30
|
Subject Assessed Change in Mean Spasticity Numerical Rating Scale (NRS) Score
Time Frame: baseline to: post-treatment (Day 0), Day 7, Day 30
|
The NRS is an 11-point scale from 0 to 10, where lower scores represent less spasticity.
|
baseline to: post-treatment (Day 0), Day 7, Day 30
|
Improvement in Pain as Assessed by Visual Analog Scale (VAS)
Time Frame: Baseline to: Post-treatment (Day 0), Day 7, Day 30
|
Visual Analog Scale assesses pain on a 0-10 point range.
0= no pain and 10 is the worst pain imaginable.
Higher score is associated with a worse outcome.
|
Baseline to: Post-treatment (Day 0), Day 7, Day 30
|
Duration of Treatment Effect
Time Frame: Day 7, Day 30, Day 56, Day 84, Day 112
|
Subjects were asked to report the duration of treatment effect at Day 7,Day 30, and Day 56.
Subjects could designate their results as "effect" "no effect" or "no longer effective".
Subjects reporting "effect" at Day 56 were followed to Day 84; those with effect at Day 84 continued to be followed to Day 112.
|
Day 7, Day 30, Day 56, Day 84, Day 112
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in spasticity
Time Frame: 7 days
|
Improvement in spasticity as measured by the Tardieu Scale.
|
7 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MYO-0709
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Limb Spasticity
-
IpsenCompletedUpper Limb SpasticityTaiwan, United States, Germany, Australia, Hong Kong, Philippines, France, Russian Federation, Italy, Portugal, Brazil, Austria, Mexico, Poland
-
Merz Pharmaceuticals GmbHCompletedUpper Limb SpasticityFrance, Spain, Switzerland, United Kingdom, Italy, Austria, Germany, Portugal
-
IpsenRecruitingUpper Limb SpasticityUnited States, France, Canada, Puerto Rico
-
IpsenCompleted
-
IpsenCompletedUpper and/or Lower Limb Focal SpasticityUnited Kingdom
-
AbbVieActive, not recruiting
-
JoAnn HarnarAllerganCompleted
-
IpsenCompletedUpper Limb Spasticity (Altered Skeletal Muscle Performance) in ChildrenUnited States, Poland, Spain, Belgium, Israel, Turkey, Czechia, Mexico
-
Mackay Memorial HospitalCompletedPost-Stroke Upper Limb SpasticityTaiwan
-
Revance Therapeutics, Inc.CompletedUpper Limb SpasticityUnited States
Clinical Trials on Treatment with Cryo-Touch III device
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedEntrapment NeuropathyUnited States
-
Pacira Pharmaceuticals, IncCompleted
-
Pacira CryoTech, Inc., a wholly owned subsidiary...Completed
-
Pacira Pharmaceuticals, IncCompletedOsteoarthritis of the KneeUnited States
-
Pacira Pharmaceuticals, IncCompletedHistological Response of Tissue to ColdUnited States
-
Pacira CryoTech, Inc., a wholly owned subsidiary...CompletedGlabellar Frown Lines | Frown LinesUnited States
-
Direction Centrale du Service de Santé des ArméesUnknownSprain of Lateral Ligament of Ankle JointFrance
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); Indiana UniversityRecruitingAtrial FibrillationUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Philips HealthcareCompleted